|
1.
|
原著(症例報告除く)
|
Identification of patients at risk for poor survival among those with normal skeletal muscle mass: a multicenter retrospective validation study in gastric cancer. 2026/09
|
|
2.
|
原著(症例報告除く)
|
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC. 2026/08
|
|
3.
|
原著(症例報告除く)
|
Clinical Impact of Anti-adhesive Materials in Preventing Postoperative Small Bowel Obstruction After Gastrectomy for Gastric Cancer: A Multicenter Observational Study Including 2,077 Patients. 2026/08
|
|
4.
|
原著(症例報告除く)
|
Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study. 2026/08
|
|
5.
|
原著(症例報告除く)
|
Laparoscopic versus open sectionectomy and bisectionectomy for hepatocellular carcinoma: a propensity score-matched analysis of short- and long-term outcomes. 2026/08
|
|
6.
|
原著(症例報告除く)
|
Association Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer. 2026/07
|
|
7.
|
原著(症例報告除く)
|
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial. 2026/07
|
|
8.
|
原著(症例報告除く)
|
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma. 2026/07
|
|
9.
|
原著(症例報告除く)
|
Postoperative Abscesses in the Liver Resection Plane in Patients with a History of Biliary Tract Treatments: A Multicenter Cohort Study. 2026/06
|
|
10.
|
その他
|
【高齢者手術の適応と周術期管理】高齢者に対する肝切除の適応判断と周術期管理 年齢ではなく「機能」で判断する 2026/06
|
|
11.
|
原著(症例報告除く)
|
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study. 2026/05
|
|
12.
|
原著(症例報告除く)
|
Prediction of microvascular invasion and post-resection prognosis using ADV, AFP-PIVKA-II, and MoRAL scores in hepatocellular carcinoma patients: an international multicenter cohort study with 9,061 patients. 2026/05
|
|
13.
|
原著(症例報告除く)
|
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. 2026/04
|
|
14.
|
原著(症例報告除く)
|
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab. 2026/04
|
|
15.
|
原著(症例報告除く)
|
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab 2026/04
|
|
16.
|
原著(症例報告除く)
|
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma. 2026/04
|
|
17.
|
その他
|
【肝門部領域胆管癌のすべて-術前管理から術後長期管理まで】術中・術後管理 仮性動脈瘤 肝門部領域胆管癌術後に発生した肝動脈仮性動脈瘤に対する止血と肝血流維持の治療戦略 2026/04
|
|
18.
|
原著(症例報告除く)
|
Proposal and external validation of a prognosis-oriented TNM staging system for intrahepatic cholangiocarcinoma: A multicenter study from the Kansai region of Japan. 2026/03
|
|
19.
|
原著(症例報告除く)
|
The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy. 2026/03
|
|
20.
|
総説
|
外科周期術の栄養療法
総論）周期術の代謝変動と栄養療法（ERASを含めて） 2026/03
|
|
21.
|
原著(症例報告除く)
|
Individualized Prognostication Based on Deep-Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection. 2026/02
|
|
22.
|
原著(症例報告除く)
|
Survival Outcomes of Gemcitabine-Cisplatin-S-1 Versus Gemcitabine-Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery 2026/02
|
|
23.
|
原著(症例報告除く)
|
Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice. 2026/02
|
|
24.
|
原著(症例報告除く)
|
Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab. 2026/01
|
|
25.
|
原著(症例報告除く)
|
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study. 2026/01
|
|
26.
|
原著(症例報告除く)
|
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis. 2026/01
|
|
27.
|
その他
|
Response to ”Sequential Portal Vein-Hepatic Vein Embolization: Progress Yet Unaccounted Pitfalls" 2026/01
|
|
28.
|
原著(症例報告除く)
|
Cachexia Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy 2026
|
|
29.
|
原著(症例報告除く)
|
Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma 2026
|
|
30.
|
原著(症例報告除く)
|
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient. 2026
|
|
31.
|
原著(症例報告除く)
|
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma. 2025/11
|
|
32.
|
原著(症例報告除く)
|
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis. 2025/11
|
|
33.
|
原著(症例報告除く)
|
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab. 2025/10
|
|
34.
|
原著(症例報告除く)
|
Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models. 2025/10
|
|
35.
|
原著(症例報告除く)
|
Defining Low Muscle Mass in Cancer Patients: Sex-Specific Computed Tomography-Derived Cutoff Values and Survival Impact-A Multicenter Cohort Study. 2025/09
|
|
36.
|
症例報告
|
Management of retrohepatic inferior vena cava injury during hepatectomy and an intravascular foreign body caused by surgical gauze migration: a case report. 2025/09
|
|
37.
|
原著(症例報告除く)
|
Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab. 2025/09
|
|
38.
|
その他
|
【集学的アプローチで挑む 胆道癌診療】肝内胆管癌に対する手術治療・術後補助化学療法 2025/09
|
|
39.
|
その他
|
【老年医学(第2版)中-基礎研究から実地診療まで-】高齢者の臓器別疾患(内科系) 消化器疾患 高齢・超高齢肝細胞癌切除例における外科治療成績と術後栄養管理の現状と課題 2025/09
|
|
40.
|
原著(症例報告除く)
|
Efficacy of Sequential Hepatic Vein Embolization Following Portal Vein Embolization in Promoting Regeneration of Liver Volume and Function Before Right-Sided Major Hepatectomy 2025/08
|
|
41.
|
原著(症例報告除く)
|
Potential Survival Benefit of Adjuvant Chemotherapy in Stage IV Intrahepatic Cholangiocarcinoma: A Multicenter, Stage-Stratified Analysis 2025/08
|
|
42.
|
その他
|
「消化器癌周術期におけるONSのエビデンスと意義」肝胆膵 2025/08
|
|
43.
|
原著(症例報告除く)
|
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma 2025/07
|
|
44.
|
原著(症例報告除く)
|
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study. 2025/07
|
|
45.
|
原著(症例報告除く)
|
Pilot Study to Assess the Ability of a 4-Week, Home-Based, Electrical Muscle Stimulation Program to Improve Lower Extremity Function and Reduce Sarcopenia in Older Individuals With Cancer. 2025/06
|
|
46.
|
原著(症例報告除く)
|
Risk for Recurrence After Liver Resection in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Detected After Sustained Virological Response by Direct-Acting Antivirals: A Retrospective Multicenter Study. 2025/06
|
|
47.
|
原著(症例報告除く)
|
Favorable impact of hepatitis C virus infection control on recurrence after surgical resection for intrahepatic cholangiocarcinoma 2025/05
|
|
48.
|
原著(症例報告除く)
|
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study. 2025/05
|
|
49.
|
原著(症例報告除く)
|
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 2025/05
|
|
50.
|
原著(症例報告除く)
|
Prognostic Significance of the BALAD Serological Model in Systemic Therapies for Hepatocellular Carcinoma: A Personalized Approach to the Prediction of Survival Benefit. 2025/05
|
|
51.
|
原著(症例報告除く)
|
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models 2025/04
|
|
52.
|
原著(症例報告除く)
|
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC 2025/04
|
|
53.
|
その他
|
【見せましょう! 外科治療における栄養療法の底力】肝臓外科における栄養療法 2025/04
|
|
54.
|
原著(症例報告除く)
|
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice 2025/03
|
|
55.
|
原著(症例報告除く)
|
Prospective Survey of Postoperative Pain in Japan: A Multicenter, Observational Study 2025/02
|
|
56.
|
その他
|
がん患者に対するElectrical Muscle Stimulation を用いたセルフリハビリテーションの治療効果検討 2025
|
|
57.
|
その他
|
がん薬物療法とDrug Delivery Syetem: レンバチニブ内包ナノファイバーシートの開発 2025
|
|
58.
|
原著(症例報告除く)
|
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab 2024/12
|
|
59.
|
原著(症例報告除く)
|
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients 2024/11
|
|
60.
|
原著(症例報告除く)
|
Risk Factors for Adhesive Small Bowel Obstruction After Liver Cancer Surgery 2024/11
|
|
61.
|
原著(症例報告除く)
|
The Prognostic Impact of Adipophilin Expression on Long-Term Survival Following Liver Resection in Patients with Colorectal Liver Metastases 2024/11
|
|
62.
|
原著(症例報告除く)
|
がん薬物療法とDrug Delivery System : レンバチニブ内包ナノファイバーシートの開発 2024/09
|
|
63.
|
原著(症例報告除く)
|
Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study 2024/08
|
|
64.
|
原著(症例報告除く)
|
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 2024/07
|
|
65.
|
原著(症例報告除く)
|
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial 2024/07
|
|
66.
|
原著(症例報告除く)
|
Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial 2024/05
|
|
67.
|
原著(症例報告除く)
|
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 2024/05
|
|
68.
|
原著(症例報告除く)
|
Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study 2024/05
|
|
69.
|
原著(症例報告除く)
|
The impact of the COVID-19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan - a multicenter collaborative observational study 2024/05
|
|
70.
|
原著(症例報告除く)
|
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study. 2024/04
|
|
71.
|
原著(症例報告除く)
|
Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study 2024/04
|
|
72.
|
原著(症例報告除く)
|
Photodynamic therapy with paclitaxel-encapsulated indocyanine green-modified liposomes for breast cancer 2024/03
|
|
73.
|
原著(症例報告除く)
|
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 2024/03
|
|
74.
|
原著(症例報告除く)
|
Laparoscopic and open minor liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a multicenter study using inverse probability weighting approach 2024/02
|
|
75.
|
原著(症例報告除く)
|
【周術期運動栄養療法】肝疾患の運動療法 2024/02
|
|
76.
|
原著(症例報告除く)
|
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma 2024/01
|
|
77.
|
原著(症例報告除く)
|
Downregulated expression of PBRM1 in sarcomatoid hepatocellular carcinoma 2024/01
|
|
78.
|
原著(症例報告除く)
|
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 2024/01
|
|
79.
|
その他
|
がん薬物療法とDrug Delivery System レンバチニブ内包ナノファイバーシートの開発 2024
|
|
80.
|
原著(症例報告除く)
|
抗VEGF療法関連高血圧に対するアンジオテンシン受容体ネプリライシン阻害薬の有効性の検討 2024
|
|
81.
|
原著(症例報告除く)
|
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach 2023/12
|
|
82.
|
原著(症例報告除く)
|
Impact of Trinal Histological Glandular Differentiation Grade on the Prognosis of Patients with Intrahepatic Cholangiocarcinoma: a Multicenter Retrospective Study 2023/12
|
|
83.
|
その他
|
【がん化学療法における代謝栄養管理の意義】がん化学療法における代謝栄養管理の意義 肝胆道がん 2023/12
|
|
84.
|
原著(症例報告除く)
|
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices 2023/11
|
|
85.
|
原著(症例報告除く)
|
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab 2023/10
|
|
86.
|
原著(症例報告除く)
|
Effect of butyrate-producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab 2023/09
|
|
87.
|
原著(症例報告除く)
|
Effect of laparoscopic liver resection on postoperative delirium in elderly patients with hepatocellular carcinoma 2023/09
|
|
88.
|
原著(症例報告除く)
|
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis 2023/08
|
|
89.
|
原著(症例報告除く)
|
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 2023/08
|
|
90.
|
原著(症例報告除く)
|
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings 2023/08
|
|
91.
|
原著(症例報告除く)
|
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma 2023/08
|
|
92.
|
原著(症例報告除く)
|
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 2023/08
|
|
93.
|
原著(症例報告除く)
|
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 2023/08
|
|
94.
|
原著(症例報告除く)
|
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study 2023/08
|
|
95.
|
原著(症例報告除く)
|
Validation of quantitative prognostic prediction using ADV score for resection of hepatocellular carcinoma: A Korea-Japan collaborative study with 9,200 patients 2023/08
|
|
96.
|
原著(症例報告除く)
|
Colonization of the gastric juice by Candida spp. promotes surgical site infection after hepatectomy 2023/06
|
|
97.
|
原著(症例報告除く)
|
Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma -clinical results show importance of hepatic reserve function 2023/06
|
|
98.
|
原著(症例報告除く)
|
Response prediction model of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: multicenter retrospective study 2023/06
|
|
99.
|
原著(症例報告除く)
|
Activities of daily living after surgery among older patients with gastrointestinal and hepatobiliary-pancreatic cancers: a retrospective observational study using nationwide health services utilisation data from Japan 2023/05
|
|
100.
|
その他
|
ASO Visual Abstract: The Prognostic Value of Preoperative Serum Markers and Risk Classification for Patients with Hepatocellular Carcinoma 2023/05
|
|
101.
|
原著(症例報告除く)
|
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 Version (5th JSH-HCC Guidelines) 2023/05
|
|
102.
|
原著(症例報告除く)
|
The Prognostic Impact of ABO Blood Group in Hepatocellular Carcinoma Following Hepatectomy 2023/05
|
|
103.
|
原著(症例報告除く)
|
The Prognostic Value of Preoperative Serum Markers and Risk Classification in Patients with Hepatocellular Carcinoma 2023/05
|
|
104.
|
原著(症例報告除く)
|
難治性腹水を生ずるA-P shuntを伴う超巨大肝血管腫に対する集学的治療経験 2023/04
|
|
105.
|
原著(症例報告除く)
|
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 2023/03
|
|
106.
|
総説
|
肝癌診療ガイドライン2021年版の改訂点 2023/03
|
|
107.
|
その他
|
Correction to: Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab. 2023/02
|
|
108.
|
原著(症例報告除く)
|
Surgical Outcomes for Hepatocellular Carcinoma in Patients with Child-Pugh Class B: a Retrospective Multicenter Study 2023/02
|
|
109.
|
原著(症例報告除く)
|
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 2023/01
|
|
110.
|
原著(症例報告除く)
|
The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan 2023/01
|
|
111.
|
原著(症例報告除く)
|
Tumor budding may be a promising prognostic indicator in intrahepatic cholangiocarcinoma: A multicenter retrospective study 2023/01
|
|
112.
|
原著(症例報告除く)
|
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 2023
|
|
113.
|
原著(症例報告除く)
|
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis 2022/12
|
|
114.
|
原著(症例報告除く)
|
Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score (mALF Score) for Predicting the Prognosis of Hepatocellular Carcinoma after Hepatectomy 2022/10
|
|
115.
|
原著(症例報告除く)
|
Surgical Outcomes of Laparoscopic versus Open Hepatectomy for Left Hepatocellular Carcinoma: Propensity Score Analyses Using Retrospective Japanese and Korean Individual Patient Data 2022/10
|
|
116.
|
原著(症例報告除く)
|
Dorsal vs ventral approach to the middle hepatic vein during laparoscopic left hemihepatectomy: multicenter retrospective observational study 2022/09
|
|
117.
|
原著(症例報告除く)
|
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice 2022/09
|
|
118.
|
総説
|
Theranostics Using Indocyanine Green Lactosomes 2022/08
|
|
119.
|
原著(症例報告除く)
|
Activation of transcription factor HIF inhibits IL-1β-induced NO production in primary cultured rat hepatocytes 2022/07
|
|
120.
|
原著(症例報告除く)
|
Risk factors for and management of morbidity in pure laparoscopic resection of the right posterosuperior segments of the liver: A multicenter retrospective study 2022/07
|
|
121.
|
症例報告
|
A case of undifferentiated carcinoma of the gallbladder with severe inflammation and difficult preoperative chemotherapy 2022/06
|
|
122.
|
原著(症例報告除く)
|
Experience with Photodynamic Therapy Using Indocyanine Green Liposomes for Refractory Cancer 2022/06
|
|
123.
|
原著(症例報告除く)
|
Comparison of the New Neo-Glasgow Prognostic Score Based on the Albumin-Bilirubin Grade with Currently Used Nutritional Indices for Prognostic Prediction following Surgical Resection of Hepatocellular Carcinoma: A Multicenter Retrospective Study in Japan 2022/04
|
|
124.
|
原著(症例報告除く)
|
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models 2022/04
|
|
125.
|
原著(症例報告除く)
|
Efficacy of nanofiber sheets incorporating lenvatinib in a hepatocellular carcinoma xenograft model 2022/04
|
|
126.
|
原著(症例報告除く)
|
Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Score-Matched Cohort Study 2022/04
|
|
127.
|
原著(症例報告除く)
|
Clinical impact of laparoscopic surgery and adhesion prevention material for prevention of small bowel obstruction 2022/03
|
|
128.
|
原著(症例報告除く)
|
Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models 2022/03
|
|
129.
|
原著(症例報告除く)
|
Predicting Complications following Surgical Resection of Hepatocellular Carcinoma Using Newly Developed Neo-Glasgow Prognostic Score with ALBI Grade: Comparison of Open and Laparoscopic Surgery Cases 2022/03
|
|
130.
|
原著(症例報告除く)
|
Prospective Study to Evaluate the Safety and Efficacy of a New Surgical Tube Fixation Method: A Pilot Study 2022/03
|
|
131.
|
原著(症例報告除く)
|
Treatment strategy for resectable colorectal cancer liver metastases from the viewpoint of time to surgical failure 2022/03
|
|
132.
|
原著(症例報告除く)
|
Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period 2022/02
|
|
133.
|
原著(症例報告除く)
|
Postoperative loss of independence 1 year after liver resection: prospective multicentre study 2022/02
|
|
134.
|
原著(症例報告除く)
|
Role of Substance P-Dependent Chemotactic Signaling in Postoperative Adhesion Formation 2022/02
|
|
135.
|
原著(症例報告除く)
|
The Impact of a Preoperative Staging System on Accurate Prediction of Prognosis in Intrahepatic Cholangiocarcinoma 2022/02
|
|
136.
|
原著(症例報告除く)
|
Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma 2022/01
|
|
137.
|
原著(症例報告除く)
|
The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion 2022/01
|
|
138.
|
原著(症例報告除く)
|
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma 2022
|
|
139.
|
症例報告
|
Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma 2021/12
|
|
140.
|
原著(症例報告除く)
|
Update on perioperative management of patients undergoing surgery for liver cancer 2021/12
|
|
141.
|
原著(症例報告除く)
|
【これまで実践してきたERAS術後早期回復プログラムの問題点は何か】肝癌肝切除におけるESSENSEに基づいた周術期管理についての検討 2021/12
|
|
142.
|
原著(症例報告除く)
|
Effect of hydrogen gas inhalation on patient QOL after hepatectomy: protocol for a randomized controlled trial 2021/10
|
|
143.
|
原著(症例報告除く)
|
Prognostic impact of neoadjuvant chemotherapy in patients with synchronous colorectal liver metastasis: A propensity score matching comparative study 2021/10
|
|
144.
|
原著(症例報告除く)
|
Preoperative Risk Assessment for Loss of Independence Following Hepatic Resection in Elderly Patients: A Prospective Multicenter Study. 2021/09
|
|
145.
|
その他
|
【消化器外科における高齢者手術-各施設の工夫と留意点】高齢者に対する肝臓手術の工夫と留意点 2021/09
|
|
146.
|
原著(症例報告除く)
|
Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey 2021/08
|
|
147.
|
その他
|
【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 切除不能肝細胞癌に対するアテゾリズマブ+ベバシズマブ療法の腫瘍縮小効果 2021/08
|
|
148.
|
原著(症例報告除く)
|
The percutaneous tandem drainage technique for radical treatment of intractable hepaticojejunostomy leakage 2021/06
|
|
149.
|
原著(症例報告除く)
|
Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma 2021/05
|
|
150.
|
原著(症例報告除く)
|
Investigation of a Tumor Location-Specific Therapeutic Strategy for Intrahepatic Cholangiocarcinoma 2021/05
|
|
151.
|
原著(症例報告除く)
|
Risk factors for incisional hernia according to different wound sites after open hepatectomy using combinations of vertical and horizontal incisions: A multicenter cohort study 2021/05
|
|
152.
|
症例報告
|
Subcapsular hepatic hematoma: a case of chronic expanding hematoma of the liver 2021/05
|
|
153.
|
原著(症例報告除く)
|
The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma 2021/04
|
|
154.
|
その他
|
【専門医必携 新外科手術書-新しい手術手技のエッセンス】肝胆膵 肝頭側(S7,S8)病変に対する腹腔鏡下切除術の手術手技 2021/04
|
|
155.
|
総説
|
Near-Infrared Fluorescence Imaging and Photodynamic Therapy for Liver Tumors 2021/02
|
|
156.
|
原著(症例報告除く)
|
Perioperative Geriatric Assessment as A Predictor of Long-Term Hepatectomy Outcomes in Elderly Patients with Hepatocellular Carcinoma 2021/02
|
|
157.
|
その他
|
【肝・胆道系症候群(第3版)-その他の肝・胆道系疾患を含めて-肝臓編(下)】肝腫瘍 原発性肝肉腫 肝血管肉腫 2021/02
|
|
158.
|
その他
|
【肝・胆道系症候群(第3版)-その他の肝・胆道系疾患を含めて-肝臓編(下)】肝腫瘍 原発性肝肉腫 肝骨肉腫 2021/02
|
|
159.
|
その他
|
【肝・胆道系症候群(第3版)-その他の肝・胆道系疾患を含めて-肝臓編(下)】肝腫瘍 原発性肝肉腫 肝脂肪肉腫 2021/02
|
|
160.
|
その他
|
【肝・胆道系症候群(第3版)-その他の肝・胆道系疾患を含めて-肝臓編(下)】肝腫瘍 原発性肝肉腫 肝線維肉腫 2021/02
|
|
161.
|
その他
|
【肝・胆道系症候群(第3版)-その他の肝・胆道系疾患を含めて-肝臓編(下)】肝腫瘍 原発性肝肉腫 肝類上皮血管内皮腫 2021/02
|
|
162.
|
その他
|
【肝・胆道系症候群(第3版)-その他の肝・胆道系疾患を含めて-肝臓編(下)】肝腫瘍 原発性肝肉腫 原発性肝平滑筋肉腫 2021/02
|
|
163.
|
原著(症例報告除く)
|
Preoperative Risk Assessment for Delirium After Hepatic Resection in the Elderly: a Prospective Multicenter Study 2021/01
|
|
164.
|
原著(症例報告除く)
|
Autologous Blood Donation Before Hepatectomy in Patients With Chronic Kidney Disease 2021
|
|
165.
|
その他
|
【肝癌治療の最前線】高齢者にかかわる問題 高齢者肝癌の手術適応の再考 2020/11
|
|
166.
|
その他
|
【消化器・一般外科手術における感染対策・周術期管理】肝臓手術における感染対策・周術期管理 2020/11
|
|
167.
|
原著(症例報告除く)
|
Mortality analysis of Aeromonas hydrophila infection in hepato-biliary pancreatic surgery: Multicenter retrospective observational study 2020/10
|
|
168.
|
原著(症例報告除く)
|
New Hepatic Resection Criteria for Intermediate-Stage Hepatocellular Carcinoma Can Improve Long-Term Survival: A Retrospective, Multicenter Collaborative Study 2020/10
|
|
169.
|
その他
|
Correction To: Antiinflammatory Constituents of Atractylodes Chinensis Rhizome Improve Glomerular Lesions in Immunoglobulin A Nephropathy Model Mice 2020/06
|
|
170.
|
原著(症例報告除く)
|
Effectiveness of Photodynamic Screening Using 5-Aminolevulinic Acid for the Diagnosis of Pancreatic Cancer 2020/06
|
|
171.
|
原著(症例報告除く)
|
Impact of systematic segmentectomy for small hepatocellular carcinoma 2020/06
|
|
172.
|
原著(症例報告除く)
|
Surgical Outcomes of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Korea-Japan Multicenter Study. 2020/05
|
|
173.
|
原著(症例報告除く)
|
Validation and performance of three-level procedure-based classification for laparoscopic liver resection. 2020/05
|
|
174.
|
原著(症例報告除く)
|
Cinnamomi Cortex and Scutellariae Radix in Japanese herbal medicine Kampo saireito inhibit expression of iNOS through different mechanisms in hepatocytes 2020/04
|
|
175.
|
その他
|
【高齢者に対する消化器外科治療】高齢者肝癌の治療戦略 2020/03
|
|
176.
|
原著(症例報告除く)
|
Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: a multi-centre propensity score-based analysis. 2020/02
|
|
177.
|
その他
|
【術前から術後まで管理栄養士はどうかかわる?よくわかる周術期の栄養管理Q&A15】ERASって何? 2020/02
|
|
178.
|
その他
|
【術前から術後まで管理栄養士はどうかかわる?よくわかる周術期の栄養管理Q&A15】ESSENSEって何? 2020/02
|
|
179.
|
原著(症例報告除く)
|
Antiinflammatory constituents of Atractylodes chinensis rhizome improve glomerular lesions in immunoglobulin A nephropathy model mice. 2020/01
|
|
180.
|
原著(症例報告除く)
|
Perioperative management for gastrointestinal surgery after instituting interventions initiated by the Japanese Society of Surgical Metabolism and Nutrition. 2020/01
|
|
181.
|
原著(症例報告除く)
|
Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models. 2019/12
|
|
182.
|
原著(症例報告除く)
|
Landscape of education and clinical practice in geriatric oncology: a Japanese nationwide survey 2019/12
|
|
183.
|
原著(症例報告除く)
|
Active Hexose Correlated Compound has Protective Effects in Ischemia-Reperfusion Injury of the Rat Small Intestine. 2019/11
|
|
184.
|
原著(症例報告除く)
|
Effects of medicinal plant ipe on expression of inducible nitric oxide synthase in inerleukin-1β-stimulated Hepatocytes 2019/10
|
|
185.
|
原著(症例報告除く)
|
The Proton Pump Inhibitor Lansoprazole Has Hepatoprotective Effects in In Vitro and In Vivo Rat Models of Acute Liver Injury. 2019/10
|
|
186.
|
原著(症例報告除く)
|
Levosimendan pretreatment improves survival of septic rats after partial hepatectomy and suppresses iNOS induction in cytokine-stimulated hepatocytes. 2019/09
|
|
187.
|
原著(症例報告除く)
|
Near-infrared fluorescence imaging and photodynamic therapy with indocyanine green lactosomes has antineoplastic effects for gallbladder cancer. 2019/09
|
|
188.
|
原著(症例報告除く)
|
【ICG蛍光法を用いた肝胆道外科手術】ICG蛍光法を用いた肝切除後胆汁漏予防 2019/09
|
|
189.
|
原著(症例報告除く)
|
Perioperative exercise capacity in chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. 2019/08
|
|
190.
|
原著(症例報告除く)
|
Essential amino acid tryptophan inhibits induction of inducible nitric oxide synthase gene expression in interleukin-1β stimulated hepatocytes 2019/07
|
|
191.
|
原著(症例報告除く)
|
Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. 2019/07
|
|
192.
|
その他
|
【肝胆膵外科手術におけるトラブルシューティング】肝臓 開腹肝切除術における肝門部操作の際の門脈・動脈損傷に対する対処法 2019/06
|
|
193.
|
原著(症例報告除く)
|
Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey. 2019/04
|
|
194.
|
原著(症例報告除く)
|
Validation of index-based IWATE criteria as an improved difficulty scoring system for laparoscopic liver resection. 2019/04
|
|
195.
|
原著(症例報告除く)
|
Preoperative weight loss program involving a 20-day very low-calorie diet for obesity before laparoscopic gastrectomy for gastric cancer. 2019/01
|
|
196.
|
総説
|
【新しい時代を迎える肝細胞癌の薬物治療と展望】 ソラフェニブによる肝細胞癌治療の実績と今後の展望 2019/01
|
|
197.
|
原著(症例報告除く)
|
Glutathione inhibits expression of the proinflammatory biomarker inducible nitric oxide synthase in hepatocytes 2018/12
|
|
198.
|
原著(症例報告除く)
|
Inhibitors of the VEGF Receptor Suppress HeLa S3 Cell Proliferation via Misalignment of Chromosomes and Rotation of the Mitotic Spindle, Causing a Delay in M-Phase Progression. 2018/12
|
|
199.
|
原著(症例報告除く)
|
Reply to "Relative Survival Instead of Overall Survival Should be Used as Outcome When Analyzing the Effect of Age After Treatment of Hepatocellular Carcinoma". 2018/12
|
|
200.
|
症例報告
|
Resection for Primary Retroperitoneal Serous Adenocarcinoma and Liver Metastasis. 2018/12
|
|
201.
|
その他
|
【外科治療における運動療法の効果】 肝臓外科における運動療法 2018/12
|
|
202.
|
原著(症例報告除く)
|
ラット敗血症モデルに対する誘導型一酸化窒素合成酵素mRNAをターゲットとした新規核酸医薬(センスオリゴヌクレオチド)の開発研究 2018/12
|
|
203.
|
原著(症例報告除く)
|
Prognostic factors of hepatectomy in initially unresectable colorectal liver metastasis: Indication for conversion therapy. 2018/11
|
|
204.
|
その他
|
【術前・術中イメージングの最先端】 術中イメージング 肝癌同定法の基礎と応用 2018/10
|
|
205.
|
原著(症例報告除く)
|
Preoperative assessment of frailty predicts age-related events after hepatic resection: a prospective multicenter study. 2018/08
|
|
206.
|
その他
|
【老年医学(下)-基礎・臨床研究の最新動向-】 高齢者の臓器別疾患 消化器疾患 高齢肝細胞癌に対する外科治療成績の現状と課題 2018/08
|
|
207.
|
その他
|
肝細胞癌術後再発転移に対するソラフェニブ治療例における長期生存例の検討 2018/06
|
|
208.
|
原著(症例報告除く)
|
A randomized controlled trial of running versus interrupted subcuticular sutures for skin closure in open gastric surgery 2018/05
|
|
209.
|
原著(症例報告除く)
|
細菌混入試験および細菌残留試験による各種静脈ライン用ニードルレスコネクタの比較検討 2018/05
|
|
210.
|
原著(症例報告除く)
|
Loss of skeletal muscle mass in patients with chronic liver disease is related to decrease in bone mineral density and exercise tolerance 2018/04
|
|
211.
|
原著(症例報告除く)
|
【外科領域におけるドレーンの適正使用】 当科での肝臓手術における腹腔ドレーンの使用状況と問題点 2018/04
|
|
212.
|
その他
|
特集：外科領域におけるドレーンの適正使用 巻頭言 2018/04
|
|
213.
|
原著(症例報告除く)
|
L-Carnitine has a live-protective effect through inhibition of inducible nitric oxide synthase induction in primary cultured rat hepatocytes 2018/03
|
|
214.
|
原著(症例報告除く)
|
Metformin inhibits expression of the proinflammatory biomarker inducible nitric oxide synthase in hepatocytes 2018/03
|
|
215.
|
原著(症例報告除く)
|
Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. 2018/03
|
|
216.
|
その他
|
【腹壁瘢痕ヘルニアの予防と治療】 腹壁瘢痕ヘルニアを予防する腹壁閉鎖法 2018/03
|
|
217.
|
原著(症例報告除く)
|
【高齢者における代謝栄養管理】 高齢者に対する肝胆膵外科治療 2018/02
|
|
218.
|
原著(症例報告除く)
|
Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis 2018/01
|
|
219.
|
原著(症例報告除く)
|
Ratio of mean platelet volume to platelet count is a potential surrogate marker predicting liver cirrhosis. 2018/01
|
|
220.
|
症例報告
|
Hepatectomy in a case of hepatocellular carcinoma with constitutional indocyanine green excretory defect. 2018
|
|
221.
|
原著(症例報告除く)
|
肝癌外科術後再発進行症例に対するソラフェニブ投与奏効例のバイオマーカーFGF19検討 2017/12
|
|
222.
|
原著(症例報告除く)
|
A sense oligonucleotide to inducible nitric oxide synthase mRNA increases the survival rate of rats in septic shock. 2017/11
|
|
223.
|
原著(症例報告除く)
|
Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma 2017/11
|
|
224.
|
症例報告
|
Combination therapies for primary hepatic neuroendocrine carcinoma: a case report. 2017/09
|
|
225.
|
原著(症例報告除く)
|
Curcumin protects liver inflammation by suppressing expression of inducible nitric oxide synthase in primary cultured rat hepatocytes 2017/09
|
|
226.
|
原著(症例報告除く)
|
Near-infrared fluorescence imaging and photodynamic therapy with indocyanine green lactosome has antineoplastic effects for hepatocellular carcinoma. 2017/08
|
|
227.
|
その他
|
【肝細胞癌の化学療法が変わる】 ソラフェニブ治療の有効性 肝癌切除後多発再発に対するソラフェニブの有用性とバイオマーカー探索 外科医の視点より 2017/08
|
|
228.
|
症例報告
|
Lymphoepithelioma-like hepatocellular carcinoma: a case report with emphasis on the cytological features 2017/07
|
|
229.
|
原著(症例報告除く)
|
静脈ライン用ニードルレスコネクタにおけるシリンジ挿入抵抗および接続確実性の比較検討 2017/07
|
|
230.
|
原著(症例報告除く)
|
Elental® amino acid component has protective effects on primary cultured hepatocytes and a rat model of acute liver injury 2017/06
|
|
231.
|
総説
|
【サルコペニアを知ろう!】 肝癌におけるサルコペニアおよび筋肉脂肪化の意義 2017/06
|
|
232.
|
原著(症例報告除く)
|
Low Incidence of Lymph Node Metastasis After Resection of Hepatitis Virus-Related Intrahepatic Cholangiocarcinoma 2017/04
|
|
233.
|
原著(症例報告除く)
|
Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma. Cancer Invest. 2017/04
|
|
234.
|
その他
|
Single-Center Experience with Subvesical Bile Ducts(Ducts of Luschka) 2017/02
|
|
235.
|
その他
|
【進行肝細胞癌に対する治療戦略(集学的治療を含めて)】 外科的治療 肝細胞癌肝外転移に対する外科治療 2017/02
|
|
236.
|
その他
|
【手術部位感染の予防と治療】 ドレーンの選択と術後管理 2017/01
|
|
237.
|
原著(症例報告除く)
|
Genipin inhibits the induction of inducible nitric oxide synthase through the inhibition of NF-κB activation in rat hepatocytes. 2017
|
|
238.
|
原著(症例報告除く)
|
Surgical Outcomes for the Ruptured Hepatocellular Carcinoma: Multicenter Analysis with a Case-Controlled Study 2016/12
|
|
239.
|
原著(症例報告除く)
|
Questionnaire survey on work motivations of gastrointestinal and hepatobiliary pancreatic surgeons enrolled in a Japanese national interdisciplinary program 2016/11
|
|
240.
|
原著(症例報告除く)
|
【新規技術が創り出す肝疾患診療のスペクタクル】 治療への応用 肝切除navigation systemを用いた手術 シミュレーションからナビゲーションへ 2016/11
|
|
241.
|
その他
|
Surgical Outcomes for the Spontaneous Rupture of Hepatocellular Carcinoma: Multicenter Analysis with a Case-Controlled Study with Propensity Score Matching 2016/10
|
|
242.
|
その他
|
【周囲神経・血管・リンパ節までまるわかり!外科ナース・研修医のための消化器の手術&臓器のはたらき】 (5章)肝臓 だから肝臓手術後はどう注意する? 2016/10
|
|
243.
|
原著(症例報告除く)
|
Japanese Kampo Saireito Has a Liver-protective Effect Through the Inhibition of Inducible Nitric Oxide Synthase Induction in Primary Cultured Rat Hepatocytes 2016/09
|
|
244.
|
原著(症例報告除く)
|
Survival outcome of salvage hepatectomy in patients with local, recurrent hepatocellular carcinoma who underwent radiofrequency ablation as their first treatment 2016/09
|
|
245.
|
原著(症例報告除く)
|
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment 2016/08
|
|
246.
|
原著(症例報告除く)
|
Staple-Line Reinforcement of the Duodenal Stump With Intracorporeal Lembert's Sutures in Laparoscopic Distal Gastrectomy With Roux-en-Y Reconstruction for Gastric Cancer 2016/08
|
|
247.
|
症例報告
|
肝癌と鑑別困難であったIgG4関連疾患の2例 2016/08
|
|
248.
|
原著(症例報告除く)
|
Evaluation of fluorescence imaging with indocyanine green in hepatocellular carcinoma 2016/04
|
|
249.
|
原著(症例報告除く)
|
Intraoperative Detection of Superficial Liver Tumors by Fluorescence Imaging Using Indocyanine Green and 5-aminolevulinic Acid 2016/04
|
|
250.
|
原著(症例報告除く)
|
Geriatric assessment as a predictor of postoperative complications in elderly patients with hepatocellular carcinoma 2016/03
|
|
251.
|
その他
|
術後回復を助けるための"エッセンス"10項目 (項目10)全体 "いまの周術期患者教育"はこのように行う! 2015/11
|
|
252.
|
その他
|
術後回復を助けるための"エッセンス"10項目 (項目5)術後 術後の痛みのコントロールはナースが担う役割! 2015/11
|
|
253.
|
その他
|
術後回復を助けるための"エッセンス"10項目 (項目9)術後 リハビリテーションは術当日から!目標設定が大切 2015/11
|
|
254.
|
その他
|
肝細胞癌に対する門脈枝塞栓術 2015/08
|
|
255.
|
原著(症例報告除く)
|
Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing Hepatocellular Carcinoma Resection 2015/07
|
|
256.
|
症例報告
|
肝細胞癌術後再発に対してSorafenib少量投与を行い長期間Stable Diseaseとなった2症例 2015/07
|
|
257.
|
その他
|
消化器外科手術後の痛み評価と鎮痛対策 2015/07
|
|
258.
|
原著(症例報告除く)
|
Fluorescence cytology with 5-aminolevulinic acid in EUS-guided FNA as a method for differentiating between malignant and benign lesions 2015/06
|
|
259.
|
その他
|
肝切除術における真皮縫合の有用性 2015/06
|
|
260.
|
その他
|
集学的治療の一環としてソラフェニブを主軸に治療した患者における肝予備能の検討 2015/06
|
|
261.
|
その他
|
高度脈管侵襲を伴う切除不能進行肝細胞癌に対するSorafenib+Cisplatin分割肝動注併用療法の第1/2相臨床試験 2015/05
|
|
262.
|
原著(症例報告除く)
|
Influence of rictor and raptor expression of mtor signaling on long-term outcomes of patients with hepatocellular carcinoma 2015/04
|
|
263.
|
その他
|
Sorafenibの投与後に外科治療を施行しえた進行肝細胞癌の4例 2015/04
|
|
264.
|
その他
|
肝癌外科術後の再発進行症例に対するソラフェニブ投与奏効症例の多施設共同検討 2015/04
|
|
265.
|
その他
|
当科での切除不能進行肝細胞癌に対するsorafenib治療例における予後因子に関する検討 2015/04
|
|
266.
|
その他
|
肝癌の予後に影響する病態・合併症 肝癌とサルコペニア 2015/03
|
|
267.
|
その他
|
Alpha-lipoic acid exerts a liver-protective effect in acute liver injury rats 2015/02
|
|
268.
|
その他
|
Do patients with small solitary hepatocellular carcinomas without macroscopically vascular invasion require anatomic resection? Propensity score analysis. 2015/01
|
|
269.
|
その他
|
Late-onset bile leakage after hepatic resection 2015/01
|
|
270.
|
その他
|
pyroGlu-Leu inhibits the induction of inducible nitric oxide synthase in interleukin-1β-stimulated primary cultured rat hepatocytes 2015/01
|
|
271.
|
その他
|
発癌予防のための治療戦略 BCAA製剤 サルコペニアに対するBCAA効果 2015/01
|
|
272.
|
原著(症例報告除く)
|
Inducible Nitric Oxide Synthase Expression in Liver Injury: Liver Protective Effects on Primary Rat Hepatocytes 2015
|
|
273.
|
その他
|
肝 肝動脈損傷,胆汁漏,胆管損傷への対応 2014/11
|
|
274.
|
症例報告
|
切除可能大腸癌肝転移症例に対する術前化学療法の意義に関する多施設共同研究 2014/11
|
|
275.
|
症例報告
|
特集：高齢者の術後早期回復はどこまで可能か？-現実と課題- 高齢肝がん患者の術後早期回復のための課題 2014/11
|
|
276.
|
症例報告
|
腹腔鏡下肝切除における手術手技の工夫 2014/11
|
|
277.
|
症例報告
|
High survival in patients operated for small isolated liver metastases from gastric cancer: a multi-institutional study. 2014/10
|
|
278.
|
症例報告
|
Higher complication rate in hepatocellular carcinoma patients undergoing prophylactic cholecystectomy with curative hepatic resection 2014/10
|
|
279.
|
その他
|
Pain Visionを用いた術後の疼痛評価 2014/10
|
|
280.
|
症例報告
|
Antibiotic prophylaxis in laparoscopic cholecystectomy: a randomized controlled trial 2014/09
|
|
281.
|
原著(症例報告除く)
|
Temporal and spatial dependence of inflammatory biomarkers and suppression by fluvastatin in dextran sodium sulfate-induced rat colitis model 2014/09
|
|
282.
|
症例報告
|
Adenosine, a hepato-protective component in active hexose correlated compound: Its identification and iNOS suppression mechanism 2014/08
|
|
283.
|
原著(症例報告除く)
|
Comparison of Tc-99m GSA scintigraphy and CT volumetry for evaluation in portal vein embolization 2014/08
|
|
284.
|
症例報告
|
The long-term outcomes after curative resection for mass-forming intrahepatic cholangiocarcinoma associated with hepatitis C viral infection: A multicenter analysis by Osaka Hepatic Surgery Study Group 2014/08
|
|
285.
|
その他
|
肝癌患者の栄養管理 チーム医療による術前術後フォローアップ 2014/08
|
|
286.
|
その他
|
肝細胞癌 高齢者肝細胞癌切除成績よりみた外科手術治療指針と周術期管理について 2014/08
|
|
287.
|
その他
|
高齢者手術の周術期栄養管理における成績評価上の問題点 2014/08
|
|
288.
|
症例報告
|
進行肝細胞癌の周術期ならびに術後化学療法施行時における癌免疫栄養療法に関する検討 2014/08
|
|
289.
|
症例報告
|
Interleukin-1β induces tumor necrosis factor-α secretion from rat hepatocytes 2014/05
|
|
290.
|
その他
|
肝胆膵外科領域における術後回復促進策実践での問題点 2014/04
|
|
291.
|
症例報告
|
日本外科代謝栄養学会評議員在籍施設における周術期管理の現状 2014/04
|
|
292.
|
症例報告
|
肝障害併存肝細胞癌切除術における術中予防的抗菌薬投与時間の腎機能別検討 2014/02
|
|
293.
|
症例報告
|
Bone marrow cells enhance liver regeneration after massive hepatectomy in mice. 2014/01
|
|
294.
|
症例報告
|
肝細胞癌肝切除後の合併症対策 危険因子に関する検討 2014/01
|
|
295.
|
その他
|
A prospective randomized controlled trial of hemostasis with a bipolar sealer during hepatic transection for liver resection. 2013/11
|
|
296.
|
その他
|
肝シミュレーション技術の現状と展望 2013/11
|
|
297.
|
その他
|
集学的治療によりCRが得られた進行再発肝細胞癌1例 2013/11
|
|
298.
|
原著(症例報告除く)
|
当科での肝細胞癌切除術における貯血式自己血輸血の有用性に関する検討 2013/11
|
|
299.
|
その他
|
チームで行う研究-各分野からのアプローチ 2013/10
|
|
300.
|
その他
|
Perioperative exercise for chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. 2013/08
|
|
301.
|
その他
|
肝細胞癌術後長期無再発生存のための術前および術後血小板数維持の意義 2013/08
|
|
302.
|
その他
|
肝実質切離における凝固機器のランダム化比較試験 2013/08
|
|
303.
|
その他
|
肝障害と誘導型一酸化窒素合成酵素 ラット初代培養肝細胞を用いた肝保護試薬のスクリーニング 2013/08
|
|
304.
|
その他
|
高齢者周術期の栄養管理 2013/08
|
|
305.
|
その他
|
Assessment of preoperative exercise capacity in hepatocellular carcinoma patients with chronic liver injury undergoing hepatectomy. 2013/07
|
|
306.
|
その他
|
Fluvastatin inhibits the induction of inducible nitric oxide synthase, an inflammatory biomarker, in hepatocytes. 2013/07
|
|
307.
|
その他
|
Novel Liver Visualization and Surgical Simulation System. 2013/06
|
|
308.
|
その他
|
あなたの?にズバリお答えします!栄養療法のギモンQ&A100+9 臨床応用編 第3章 消化器疾患 2013/05
|
|
309.
|
その他
|
胆道結石症および肝膿瘍治療後に確認された肝内胆管癌の1例 2013/05
|
|
310.
|
その他
|
Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma. 2013/04
|
|
311.
|
その他
|
Natural antisense transcript-targeted regulation of inducible nitric oxide synthase mRNA levels. 2013/04
|
|
312.
|
その他
|
高齢者肝細胞癌肝切除術に対する外科治療成績 2013/04
|
|
313.
|
その他
|
障害肝合併肝細胞癌患者の周術期BCAA顆粒製剤投与を含めた運動・栄養療法の臨床効果 2013/04
|
|
314.
|
その他
|
肝がん肝切除手術における運動療法とは? 2013/01
|
|
315.
|
その他
|
Sorafenib alone versus a combination of sorafenib and ninjin 'yoeito for the treatment of patients with advanced hepatocellular carcinoma : a retrospenctive study and pharmacological study in rats 2013
|
|
316.
|
その他
|
第20回日本消化器関連学会週間MeetingReport 2013
|
|
317.
|
その他
|
臨床と研究 肝切除手術手技の実態に関する多施設アンケート調査方向－大阪府下5大学およびその関連28施設の現状－ 2012/12
|
|
318.
|
その他
|
Absence of cystic duct leakage using locking clips in 1017 cases of laparoscopic cholecystectomy. 2012/11
|
|
319.
|
その他
|
眼球脈絡膜原発悪性黒色腫の肝転移に対し肝切除術を行った1例 2012/11
|
|
320.
|
その他
|
術前化学療法による画像上CR症例に対し肝切除した大腸癌肝転移の1例 2012/11
|
|
321.
|
その他
|
Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. 2012/09
|
|
322.
|
その他
|
タコシール症例 肝臓外科領域 肝臓外科手術におけるERASプロトコール 2012/08
|
|
323.
|
その他
|
大腸癌肝転移に対する肝切除術を考慮した術前化学療法 2012/08
|
|
324.
|
原著(症例報告除く)
|
Novel Strategy for the Control of Postoperative Pain: Long-Lasting Effect of an Implanted Analgesic Hydrogel in a Rat Model of Postoperative Pain. 2012/06
|
|
325.
|
その他
|
A Prospective Randomized Controlled Trial of Preoperative Whole-Liver Chemolipiodolization for Hepatocellular Carcinoma. 2012/05
|
|
326.
|
その他
|
Stimulation of Liver Regeneration After Hepatectomy in Mice by Injection of Bone Marrow Mesenchymal Stem Cells via the Portal Vein. 2012/05
|
|
327.
|
その他
|
肝MALTリンパ腫の1例 2012/05
|
|
328.
|
その他
|
肝臓外科手術におけるERASプロトコールの導入 2012/05
|
|
329.
|
症例報告
|
FDG-PETで集積亢進を認めた肝血管筋脂肪腫の1例 2012/04
|
|
330.
|
原著(症例報告除く)
|
α-Lipoic Acid Prevents the Induction of iNOS Gene Expression Through Destabilization of Its mRNA in Proinflammatory Cytokine-Stimulated Hepatocytes. 2012/04
|
|
331.
|
その他
|
Change in donor quality of life after living donor liver transplantation surgery: a single-institution experience. 2012/03
|
|
332.
|
その他
|
Predictors and outcome of early recurrence after resection of hepatic metastases from colorectal cancer. 2012/03
|
|
333.
|
原著(症例報告除く)
|
ソラフェニブ投与進行肝細胞癌患者に対する人参養栄湯の併用効果の検討 2012/03
|
|
334.
|
その他
|
肝疾患 その他の肝腫瘍 2012/03
|
|
335.
|
その他
|
Japanese herbal medicine, inchinkoto, inhibits inducible nitric oxide synthase induction in interleukin-1β-stimulated hepatocytes. 2012/01
|
|
336.
|
その他
|
3D Visualization of Liver and Its Vascular Structures and Surgical
Planning System －Surgical Simulation－ 2011/11
|
|
337.
|
その他
|
Active Hexose Correlated Compound Inhibits the Expression of Proinflammatory Biomarker iNOS in Hepatocytes. 2011/11
|
|
338.
|
原著(症例報告除く)
|
Usefulness of Tc-99m-GSA scintigraphy for liver surgery. 2011/11
|
|
339.
|
その他
|
当科における切除不能肝細胞癌症例に対するSorafenibの治療経験 2011/11
|
|
340.
|
原著(症例報告除く)
|
Postoperative infectious and non-infectious complications after hepatectomy for hepatocellular carcinoma. 2011/09
|
|
341.
|
原著(症例報告除く)
|
肝硬変合併巨大肝細胞癌における開腹下マイクロ波凝固壊死療法の工夫 2011/08
|
|
342.
|
その他
|
Intraoperative indocyanine green fluorescent imaging for prevention of bile leakage after hepatic resection. 2011/07
|
|
343.
|
症例報告
|
被膜下血腫をきたした肝細胞癌の1例 2011/07
|
|
344.
|
その他
|
Peroxidation of n-3 Polyunsaturated Fatty Acids Inhibits the Induction of iNOS Gene Expression in Proinflammatory Cytokine-Stimulated Hepatocytes. 2011/06
|
|
345.
|
その他
|
Sivelestat Suppresses iNOS Gene Expression in Proinflammatory Cytokine-Stimulated Hepatocytes. 2011/06
|
|
346.
|
原著(症例報告除く)
|
肝細胞癌治療前後の補助療法 2011/06
|
|
347.
|
原著(症例報告除く)
|
消化器癌をめぐる栄養療法 障害肝合併肝細胞癌患者の肝切除周術期における運動・栄養療法の臨床効果 2011/06
|
|
348.
|
原著(症例報告除く)
|
肝疾患 その他の肝腫 2011/05
|
|
349.
|
その他
|
肝臓分割と血管抽出による肝臓情報の三次元可視化と手術支援システム(第2報)-肝臓三次元立体可視化と三次元ポインティングデバイスによる対話かつ直感的なシミュレーションシステムの構築- 2011/05
|
|
350.
|
その他
|
Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma. 2011/03
|
|
351.
|
その他
|
肝臓分割と血管抽出による肝臓情報の三次元可視化と手術支援システム 2011/01
|
|
352.
|
原著(症例報告除く)
|
門脈腫瘍栓を伴う進行肝細胞癌に対するSorafenib+Cisplatin分割肝動注併用療法のPilot Study 2010/12
|
|
353.
|
その他
|
Timing of Resection for Synchronous Liver Metastases from Colorectal Cancer. 2010/11
|
|
354.
|
原著(症例報告除く)
|
術後高血圧症合併によるＣ型肝炎関連肝細胞癌切除成績の検討 2010/11
|
|
355.
|
その他
|
大腸癌同時性肝転移に対する切除時期を考慮した外科治療成績 2010/08
|
|
356.
|
原著(症例報告除く)
|
機能性食品AHCCによるiNOS誘導の阻害(in vitro肝細胞を用いた''肝保護効果''を持つ食品のスクリーニング) 2010/07
|
|
357.
|
症例報告
|
肝限局性結節性過形成による下大静脈狭窄によるBudd-Chiari症候群様の血流異常を認めた1例 2010/05
|
|
358.
|
原著(症例報告除く)
|
最新の手術機器を用いた肝離断法 2010/04
|
|
359.
|
原著(症例報告除く)
|
Indocyanine green赤外観察カメラシステムを用いた肝切除後胆汁瘻防止対策についてのパイロットスタディ 2010/02
|
|
360.
|
その他
|
Dexamethasone inhibits the induction of inos gene expression through destabilization of its mrna in proinflammatory cytokine-stimulated hepatocytes 2010/01
|
|
361.
|
その他
|
Primary sclerosing cholangitis with elevated serum IgG4 levels and/or infiltration of abundant IgG4-positive plasma cells 2010/01
|
|
362.
|
その他
|
HLA抗体保有患者の生体肝移植症例 2009/12
|
|
363.
|
その他
|
自己免疫性肝炎に合併した非B非C型肝細胞癌の1切除例 2009/12
|
|
364.
|
その他
|
大腸癌肝転移H3(Grade C)初回切除不能多発症例に対する術前補助化学療法後肝切除術の成績 2009/12
|
|
365.
|
原著(症例報告除く)
|
C型肝炎関連肝細胞癌に対する系統的および非系統的肝切除の検討 2009/10
|
|
366.
|
原著(症例報告除く)
|
Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas 2009/07
|
|
367.
|
原著(症例報告除く)
|
Hepatic resection for hepatocellular carcinoma in the elderly. 2009/03
|
|
368.
|
原著(症例報告除く)
|
Edaravone inhibits the induction of iNOS gene expression at transcriptional and posttranscriptional steps in murine macrophages. 2008/12
|
|
369.
|
原著(症例報告除く)
|
HA/GSA-Rmax Ratio as a Predictor of Postoperative Liver Failure. 2008/11
|
|
370.
|
原著(症例報告除く)
|
Risk factors for early death due to recurrence after resection of large hepatocellular carcinomas 2008/11
|
|
371.
|
症例報告
|
Usefulness of TC-99M GSA Liver Scintigraphy for the Assessment of Recurrent Hepatitis C After Living-Donor Liver Transplantation: A Case Report. 2008/10
|
|
372.
|
原著(症例報告除く)
|
Usefulness of Tc-99m GSA liver scintigraphy for the evaluation of liver regeneration in donors after living-donor liver transplantation. 2008/10
|
|
373.
|
症例報告
|
広範な肝右葉被膜下膿瘍を呈した急性胆嚢炎の1例 2008/10
|
|
374.
|
原著(症例報告除く)
|
Protective effect of FR183998, a Na+/H+ exchanger inhibitor, and its inhibition of
OF iNOS induction in hepatic ischemia-reperfusion injury in rats. 2008/09
|
|
375.
|
症例報告
|
エホバの証人患者における転移性肝癌切除の1例 2008/08
|
|
376.
|
原著(症例報告除く)
|
Insulin-like growth factor 1 prevents liver injury through the inhibition of TNF-α and iNOS induction in D-galactosamine and LPS-treated rats. 2008/06
|
|
377.
|
原著(症例報告除く)
|
Impact of fresh frozen plasma on hepatectomy for hepatocellular carcinoma. 2008/05
|
|
378.
|
原著(症例報告除く)
|
Edaravone prevents iNOS expression by inhibiting its promoter transactivation and mRNA stability in cytokine-stimulated hepatocytes. 2008/03
|
|
379.
|
原著(症例報告除く)
|
Liver Regeneration in Donors Evaluated by Tc-99m-GSA Scintigraphy after Living Donor Liver Transplantation. 2008/03
|
|
380.
|
原著(症例報告除く)
|
Protective Effect of Neutrophil Elastase Inhibitor (FR136706) in Lethal Acute Liver Failure Induced by D-Galactosamine and Lipopolysaccharide in Rats. 2008/03
|
|
381.
|
原著(症例報告除く)
|
Na(+)/H(+) exchanger inhibitor, FR183998, has protective effect in lethal acute liver failure and prevents iNOS induction in rats. 2008/02
|
|
382.
|
原著(症例報告除く)
|
Natural antisense transcript stabilizes inducible nitric oxide synthase messenger RNA in rat hepatocytes 2008/02
|
|
383.
|
原著(症例報告除く)
|
Pitavastatin up-regulates the induction of iNOS through enhanced stabilization of its mRNA in pro-inflammatory cytokine-stimulated hepatocytes. 2008/02
|
|
384.
|
原著(症例報告除く)
|
Living donor liver transplantion for primary biliary cirrhosis with autoimmune hemolytic anemia: a case report. 2007/11
|
|
385.
|
原著(症例報告除く)
|
Effect of active hexose correlated compound on the production of nitric oxide in hepatocytes. 2007/09
|
|
386.
|
原著(症例報告除く)
|
Effect of thiol-containing molecule cysteamine on the induction of inducible nitric oxide synthase in hepatocytes. 2007/09
|
|
387.
|
原著(症例報告除く)
|
Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. 2007/07
|
|
388.
|
原著(症例報告除く)
|
Postoperative outcomes in patients with hepatocellular carcinomas resected with exposure of the tumor surface: clinical role of the no-margin resection. 2007/07
|
|
389.
|
原著(症例報告除く)
|
Risk factors for different patterns of recurrence after resection of hepatocellular carcinoma. 2007/07
|
|
390.
|
症例報告
|
若年者に発症した非B非C型肝細胞癌の１例 2007/05
|
|
391.
|
原著(症例報告除く)
|
A review of the prognostic factors in patients with recurrence after liver resection for hepatocellular carcinoma. 2007/04
|
|
392.
|
原著(症例報告除く)
|
Cutaneous and colonic metastases after resection of hepatocellular carcinoma. 2007/04
|
|
393.
|
症例報告
|
肝原発内分泌細胞癌の１切除例 2007/04
|
|
394.
|
原著(症例報告除く)
|
Overproduction of PGE2 in peripheral blood monocytes of gastrointestinal cancer patients with mucins in their bloodstream. 2007/01
|
|
395.
|
その他
|
99ｍＴｃ-ＧＳＡが早期診断に有用であった生体肝移植後のＣ型肝炎再発 2006
|
|
396.
|
原著(症例報告除く)
|
Administration of rhHGF-activator via portal vein stimulates the regeneration of cirrhotic liver after partial hepatectomy in rats. 2006
|
|
397.
|
原著(症例報告除く)
|
Comparison of limited and anatomic hepatic resection for hepatocellular carcinoma with hepatitis C. 2006
|
|
398.
|
原著(症例報告除く)
|
Hepatic ischemia/reperfusion upregulates the susceptibility of hepatocytes to confer the induction of inducible nitric oxide synthase gene expression. 2006
|
|
399.
|
原著(症例報告除く)
|
Hepatocyte growth factor stimulates the induction of cytokine-induced neutrophil chemoattractant through the activation of NF-κB in rat hepatocytes. 2006
|
|
400.
|
原著(症例報告除く)
|
Influence of transcatheter arterial chemoembolization on the prognosis after hepatectomy for hepatocellular carcinoma in patients with severe liver dysfunction. 2006
|
|
401.
|
原著(症例報告除く)
|
Preoperative regional maximal removal rate of technetium-99m-galactosyl human serum albumin (GSA-Rmax) is useful for judging the safety of hepatic resection. 2006
|
|
402.
|
原著(症例報告除く)
|
Recurrent Hepatitis C After Living Donor liver Transplantation Detected by Tc-99m GSA Liver Scintigraphy 2006
|
|
403.
|
その他
|
【肝病態生理研究のあゆみ】99mTc-GSAアシアロシンチによるグラフト肝機能評価 2006
|
|
404.
|
その他
|
移植後にHLA抗体が検出された生体肝移植 2006
|
|
405.
|
原著(症例報告除く)
|
Enhanced production of interleukin 6 in peripheral blood monocytes stimulated with mucins secreted into the bloodstream. 2005/09
|
|
406.
|
その他
|
A case of susupected severe pulmonary embolosm in a living-related liver transplantation donor 2005
|
|
407.
|
その他
|
Clinical outcome of 214 liver resevtion using microwave tissue coagulation 2005
|
|
408.
|
原著(症例報告除く)
|
Enhanced production of interleukin 6 in peripheral blood monocytes stimulated with mucins secreted into the bloodstream. 2005
|
|
409.
|
原著(症例報告除く)
|
Free radical scavenger (edaravone) prevents endotoxin-induced liver injury after partial hepatectomy in rats. 2005
|
|
410.
|
その他
|
Hepaocyte growth factor stimulates the induction of cytokine-induced nentrophil chemoattractant through the activation of NF-KappaB in rat 2005
|
|
411.
|
原著(症例報告除く)
|
Living donor liver transplantation in a recipient with anti-Fy(a)and Jk(a)antibodies 2005
|
|
412.
|
原著(症例報告除く)
|
Prognosis of hepatocellular carcinoma after hepatectomy in patients with renal dysfunction 2005
|
|
413.
|
原著(症例報告除く)
|
ラット肝切除後エンドトキシン血症に対するＰｉｒｆｅｎｉｄｏｎｅの生体保護効果 2005
|
|
414.
|
その他
|
肝移植後再発Ｃ型肝炎の肝アシアロシンチによる機能評価 2005
|
|
415.
|
原著(症例報告除く)
|
Cycloprodigiosin up-regulates inducible nitric oxide synthase gene expression in hepatocytes stimulated by interleukin-1beta. 2004
|
|
416.
|
原著(症例報告除く)
|
Effect of hepatocyte growth factor on induction of cytokine-induced neutrophil chemoattractant in rat hepatocytes. 2004
|
|
417.
|
原著(症例報告除く)
|
Effect of pirfenidone on induction of chemokines in rat hepatocytes. 2004
|
|
418.
|
原著(症例報告除く)
|
Effects of pirfenidone on endotoxin-induced liver injury after partial hepatectomy in rats. 2004
|
|
419.
|
原著(症例報告除く)
|
Fibronectin protects endotoxin-induced liver injury after partial hepatectomy in rats. 2004
|
|
420.
|
原著(症例報告除く)
|
Fibronectin suppresses apoptosis and protects mice from endotoxic shock. 2004
|
|
421.
|
原著(症例報告除く)
|
Functional hepatic regeneration following hepatectomy using galactosyl-human serum albumin liver scintigraphy. 2004
|
|
422.
|
原著(症例報告除く)
|
Induction of inducible nitric oxide synthase in hepatocytes isolated from rats with ischemia-reperfusion injury. 2004
|
|
423.
|
原著(症例報告除く)
|
Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes. 2004
|
|
424.
|
原著(症例報告除く)
|
Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats. 2004
|
|
425.
|
原著(症例報告除く)
|
Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats. 2004
|
|
426.
|
原著(症例報告除く)
|
Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma. 2004
|
|
427.
|
原著(症例報告除く)
|
Preoperative chemolipiodolization of the whole liver for hepatocellular carcinoma. 2004
|
|
428.
|
原著(症例報告除く)
|
Safety of hepatectomy for living donors as evaluated using asialoscintigraphy. 2004
|
|
429.
|
原著(症例報告除く)
|
Up-regulation of IL-1 receptor through PI3K/Akt is essential for the induction of iNOS gene expression in hepatocytes. 2004
|
|
430.
|
原著(症例報告除く)
|
分類不能の重複胆嚢にみられた胆嚢結石症の1例 2004
|
|
431.
|
原著(症例報告除く)
|
Effect of exogenously administered HGF activator in liver regeneration. 2003
|
|
432.
|
原著(症例報告除く)
|
Hepatic resection for hepatocellular carcinoma in severely cirrhotic livers. 2003
|
|
433.
|
原著(症例報告除く)
|
Hepatocyte growth factor inhibits insulin-stimulated glycogen synthesis in primary cultured hepatocytes. 2003
|
|
434.
|
原著(症例報告除く)
|
Intrahepatic sarcomatoid cholangiocarcinoma. 2003
|
|
435.
|
原著(症例報告除く)
|
Pancreatic islet preservation at temperatures just above the freezing point. 2003
|
|
436.
|
原著(症例報告除く)
|
Prevention of pleural effusion following hepatectomy using argon beam coagulation. 2003
|
|
437.
|
原著(症例報告除く)
|
Refractoriness to platelet transfusion following partial hepatectomy for hepatocellular carcinoma: report of two cases. 2003
|
|
438.
|
原著(症例報告除く)
|
【肝病態生理研究のあゆみ】 99mTc-GSAによる生体肝移植前後の肝機能評価(原著論文/症例報告/特集/抄録あり) 2003
|
|
439.
|
原著(症例報告除く)
|
肝癌 肝細胞癌に対するmicrowave凝固療法を用いた肝切除術 根治切除症例の検討 2003
|
|
440.
|
原著(症例報告除く)
|
肝細胞癌との鑑別を要した肝原発内分泌細胞癌の１切除例 2003
|
|
441.
|
原著(症例報告除く)
|
肝臓の糖質及び脂質代謝に及ぼす肝細胞増殖因子(HGF)の影響 2003
|
|
442.
|
原著(症例報告除く)
|
肝内胆管肉腫様癌の1例 2003
|
|
443.
|
原著(症例報告除く)
|
胆嚢原発MALTリンパ腫の1例 2003
|
|
444.
|
原著(症例報告除く)
|
80歳以上の高齢者に対する腹腔鏡下胆嚢摘出術の検討 2002
|
|
445.
|
原著(症例報告除く)
|
Exogenously administered HGF activator augments liver regeneration through the production of biologically active HGF. 2002
|
|
446.
|
原著(症例報告除く)
|
Impairment of activation of hepatocyte growth factor precursor into its mature form in rats with liver cirrhosis. 2002
|
|
447.
|
原著(症例報告除く)
|
Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. 2002
|
|
448.
|
原著(症例報告除く)
|
Increased nitric oxide production in hepatocytes is involved in liver dysfunction following obstructive jaundice. 2002
|
|
449.
|
原著(症例報告除く)
|
リコンビナントヒトHGF-activator投与によるラット肝臓の内因性proHGFの活性化 2002
|
|
450.
|
原著(症例報告除く)
|
感悪性腫瘍に対するAblation Therapy 肝細胞癌に対するMicrowave凝固壊死療法を用いた肝切除術 根治切除例の検討 2002
|
|
451.
|
症例報告
|
13歳女児に発症した膵粘液嚢胞腺腫の一例 2001
|
|
452.
|
原著(症例報告除く)
|
FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia in rat hepatocytes. 2001
|
|
453.
|
原著(症例報告除く)
|
High density O-glycosylation of the MUC2 tandem repeat unit by N-acetylgalactosaminyltransferase-3 in colonic adenocarcinoma extracts. 2001
|
|
454.
|
原著(症例報告除く)
|
Laparoscopic cholecystectomy and choledocholithotomy in patients with a previous gastrectomy. 2001
|
|
455.
|
原著(症例報告除く)
|
肝臓の低酸素障害に対するFK506の保護効果 2001
|
|
456.
|
症例報告
|
上行結腸憩室炎にcolonic muco-submucosal elongated polypを合併した1例 2001
|
|
457.
|
原著(症例報告除く)
|
当科におけるグロ-ションカテ-テルの使用経験 2001
|
|
458.
|
原著(症例報告除く)
|
膵管癒合不全を伴った膵漿液性嚢胞腺腫の1例 2001
|
|
459.
|
原著(症例報告除く)
|
Role of hepatocyte growth factor in hepatic ischemia and reperfusion injury 2000/11
|
|
460.
|
原著(症例報告除く)
|
Recombinant human hepatocyte growth factor protects the liver against hepatic ischemia and reperfusion injury in rats 2000/08
|
|
461.
|
その他
|
消化器外科手術アトラス マイクロターゼを用いた非阻血下肝部分切除術 2000/04
|
|
462.
|
原著(症例報告除く)
|
アシアロシンチを用いた機能的肝容量と肝細胞総量との関連について 2000/02
|
|
463.
|
原著(症例報告除く)
|
Hypoxia and heat inhibit inducible nitric oxide synthase gene expression by different mechanisms in rat hepatocytes 2000
|
|
464.
|
原著(症例報告除く)
|
Vicinal dithiol-binding agent, phenylarsine oxide, inhibits inducible nitric-oxide synthase gene expression at a step of nuclear factor-κB DNA binding in hepatocytes 2000
|
|
465.
|
原著(症例報告除く)
|
A novel conception for liver preservation at a temperature just above freezing point 1999
|
|
466.
|
原著(症例報告除く)
|
An enhancement of nitric oxide production regulates energy metabolism in rat hepatocytes after a partial hepatectomy 1999
|
|
467.
|
症例報告
|
Auxiliary liver transplantation for urea-cycle enzyme deficiencies: lessons from three cases. 1999
|
|
468.
|
原著(症例報告除く)
|
Ex vivo liver perfusion with arterial blood from a pig with ischemic liver failure 1999
|
|
469.
|
原著(症例報告除く)
|
Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-κB activation in rat hepatocytes 1999
|
|
470.
|
原著(症例報告除く)
|
Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes 1999
|
|
471.
|
症例報告
|
Native hepatectomy after auxiliary partial orthotopic liver transplantation. 1999
|
|
472.
|
原著(症例報告除く)
|
Selective portal blood flow diversion in auxiliary partial orthotopic liver transplantation to induce regeneration of the graft 1998/07
|
|
473.
|
原著(症例報告除く)
|
HGFの肝リポ蛋白質分泌への効果 1998/06
|
|
474.
|
原著(症例報告除く)
|
Hepatocyte growth factor stimulates synthesis of lipids and secretion of lipoproteins in rat hepatocytes 1998
|
|
475.
|
原著(症例報告除く)
|
Interleukin 1β and interleukin 6, but not tumor necrosis factor α, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes 1998
|
|
476.
|
その他
|
Living-related donor small bowel transplantation: first case in Japan. 1998
|
|
477.
|
その他
|
Strategy used to overcome graft atrophy in auxiliary partial orthotopic liver transplantation from a living donor for ornithine transcarbamylase deficiency. 1998
|
|
478.
|
総説
|
部分肝切除後の肝再生機序 1997/11
|
|
479.
|
原著(症例報告除く)
|
Stimulation of liver regeneration and function after partial hepatectomy in cirrhotic rats by continuous infusion of recombinant human hepatocyte growth factor 1997
|
|
480.
|
原著(症例報告除く)
|
硬変肝ラット部分肝切除術後のＨＧＦ持続投与による肝再生促進効果について 1997
|
|
5件表示
|
|
全件表示(480件)
|
